Icon sees more growth after 10% revenue rise
Icon, the listed outsourced pharmaceutical development firm, has announced a 10 per cent increase in revenues in the first quarter of this year.
Icon, the listed outsourced pharmaceutical development firm, believes it can increase its profit margins further in key business areas, after announcing a 10 per cent increase in revenues in the first quarter of this year.
Speaking to investors after the presentation of the company's result, chief executive Ciaran Murray said that the company could increase its Ebidta margins over the next year. "I think it's all about growing our top line and getting leverage from the...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine